Press releases
- Cybin to Present at the H.C. Wainwright Global Investment Conference on May 25, 2022
- Cybin and Kernel Announce Results from Kernel Flow® Piloting of Feasibility Study Measuring Ketamine’s Effects on the Brain
- Cybin Announces CYB003 Poster to be Presented at the ‘From Research to Reality’ Global Summit on Psychedelic-Assisted Therapies and Medicine
- Cybin to Participate in the KCSA Psychedelics Virtual Investor Conference on April 28, 2022
- Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder
- Cybin Announces Positive CYB004 Data Demonstrating Significant Advantages Over Intravenous and Inhaled DMT
- Cybin Announces Publication of International PCT Patent Application for Inhalation Delivery of Multiple Psychedelic Molecules
- Cybin to Present at the Benzinga Psychedelics Capital Conference in Miami on April 19, 2022
- Cybin Announces Additional Adelia Milestone Achievement
- Cybin Announces Initiation of Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain
More ▼
Key statistics
On Friday, Cybin Inc (CYBN:ASQ) closed at 0.411, 5.30% above its 52-week low of 0.3903, set on May 13, 2022.
52-week range
Markit short selling activity
Open | 0.43 |
---|---|
High | 0.44 |
Low | 0.3903 |
Bid | 0.42 |
Offer | 0.425 |
Previous close | 0.411 |
Average volume | 764.33k |
---|---|
Shares outstanding | 162.63m |
Free float | 115.96m |
P/E (TTM) | -- |
Market cap | 102.46m CAD |
EPS (TTM) | -0.4375 CAD |
Data delayed at least 15 minutes, as of May 13 2022 21:10 BST.
More ▼